Tonix (NASDAQ: TNXP) sets Tonmya price, hires market access head

Rhea-AI Filing Summary

Tonix Pharmaceuticals Holding Corp. appointed Ganesh Kamath as Head of Market Access, effective September 29, 2025. This role typically focuses on how medicines are reimbursed and accessed by patients through insurers and health systems.

The company also set the wholesale acquisition cost for Tonmya, its treatment for fibromyalgia in adults, at $1,860 per month for a 60‑count supply. For geriatric adults and adults with mild hepatic impairment, the wholesale acquisition cost is $930 per month for a 30‑count supply. These list prices form the starting point for insurer and pharmacy discount negotiations.

8-K Event Classification

3 items: 7.01, 8.01, 9.01

3 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001430306 0001430306 2025-09-30 2025-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): September 30, 2025

TONIX PHARMACEUTICALS HOLDING CORP. 

(Exact name of registrant as specified in its charter)

Nevada	001-36019	26-1434750
(State or Other Jurisdiction  of Incorporation)	(Commission  File Number)	(IRS Employer  Identification No.)

26 Main Street, Chatham, New Jersey, 07928 

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (862) 799-8599

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	TNXP	The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 30, 2025, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced the appointment of Ganesh Kamath as Head of Market Access, effective September 29, 2025. A copy of the press release which discusses this matter is furnished hereto as Exhibit 99.01, and incorporated herein by reference.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01. Other Events.

On September 30, 2025, the Company announced the appointment of Ganesh Kamath as Head of Market Access, effective September 29, 2025.

The Company set a wholesale acquisition cost (“WAC”) for Tonmya™ for the treatment of fibromyalgia in adults of $1,860 per month for the 60-count supply.  For geriatric patients and adult patients with mild hepatic impairment, the WAC is $930 per month for the 30-count supply.

Forward-Looking Statements

This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. 

Item 9.01 Financial Statements and Exhibits.

(d)		Exhibit No.		Description.
		99.01		Press Release of the Company, September 30, 2025
		104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	TONIX PHARMACEUTICALS HOLDING CORP.
Date: September 30, 2025	By:	/s/ Bradley Saenger
		Bradley Saenger
		Chief Financial Officer

FAQ

What did Tonix Pharmaceuticals (TNXP) report in this 8-K filing?

Tonix Pharmaceuticals Holding Corp. reported the appointment of Ganesh Kamath as Head of Market Access and disclosed the initial wholesale acquisition cost levels for Tonmya for fibromyalgia in adults.

Who is the new Head of Market Access at Tonix Pharmaceuticals (TNXP)?

Tonix Pharmaceuticals appointed Ganesh Kamath as Head of Market Access, effective September 29, 2025, to oversee how the company’s therapies are positioned for reimbursement and patient access.

What is the wholesale acquisition cost for Tonmya for fibromyalgia?

Tonix set the wholesale acquisition cost for Tonmya for treatment of fibromyalgia in adults at $1,860 per month for a 60‑count supply.

How is Tonmya priced for geriatric patients or those with mild hepatic impairment?

For geriatric patients and adult patients with mild hepatic impairment, the wholesale acquisition cost for Tonmya is $930 per month for a 30‑count supply.

Does this Tonix (TNXP) 8-K include any financial results or earnings data?

No detailed financial results or earnings metrics are discussed; the focus is on executive appointment and Tonmya pricing for fibromyalgia in adults.

Is the Tonmya price in this Tonix (TNXP) filing a list price or net cost to patients?

The amounts disclosed for Tonmya are described as the wholesale acquisition cost (WAC), which is a list price before rebates or discounts negotiated with payers and pharmacies.